Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today ...

addressing one of the major drawbacks of existing CGM devices, deemed invasive due to the requirement of a needle inserted ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

addressing one of the major drawbacks of existing CGM devices, deemed invasive due to the requirement of a needle inserted under the skin, which can cause discomfort. Additionally, a viscoelastic ...

Continuous Glucose Monitoring (CGM) Systems Market The increasing incidence of diabetes and the detection of patient's blood glucose levels are raising the demand for continuous global monitoring ...

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy be ...